Free tool
FAERS Monitor: Fosaprepitant Dimeglumine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210064 or its brand name (Fosaprepitant Dimeglumine, Fosaprepitant Dimeglumine). Reports on generic versions are filed under their own applications.
Reports
2,520
Serious
2,230
88% of reports
Hospitalization
1,262
Death reported
510
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea426
- infusion related reaction360
- alopecia335
- fatigue315
- pyrexia304
- hypersensitivity300
- nausea283
- arthralgia276
- glossodynia271
- pruritus271
- helicobacter infection270
- confusional state269
- duodenal ulcer perforation269
- pain269
- stomatitis267
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 94 |
| 2013 | 64 |
| 2014 | 79 |
| 2015 | 73 |
| 2016 | 71 |
| 2017 | 77 |
| 2018 | 142 |
| 2019 | 134 |
| 2020 | 155 |
| 2021 | 199 |
| 2022 | 274 |
| 2023 | 217 |
| 2024 | 285 |
| 2025 | 379 |
| 2026 | 265 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,639 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| duodenal ulcer perforationSignal | 269 | 313.2 | 279.1 | 80,415 |
| helicobacter infectionSignal | 270 | 225.1 | 200.8 | 58,469 |
| glossodyniaSignal | 271 | 102.3 | 91.3 | 26,775 |
| infusion related reactionSignal | 360 | 45.6 | 41.4 | 15,613 |
| stomatitisSignal | 267 | 36.9 | 32.9 | 9,276 |
| alopeciaSignal | 335 | 14.3 | 12.9 | 4,149 |
| confusional stateSignal | 269 | 13.9 | 12.4 | 3,231 |
| hypersensitivitySignal | 300 | 13.5 | 12.1 | 3,488 |
| pyrexiaSignal | 304 | 7.3 | 6.6 | 1,684 |
| dyspnoeaSignal | 426 | 6.3 | 5.8 | 1,939 |
| pruritusSignal | 271 | 5.9 | 5.3 | 1,115 |
| arthralgiaSignal | 276 | 5.5 | 5.0 | 1,043 |
| painSignal | 269 | 3.7 | 3.3 | 532 |
| fatigueSignal | 315 | 3.4 | 3.0 | 545 |
| nauseaSignal | 283 | 3.0 | 2.7 | 386 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.